Healthcare - Asia Tech Wire

Healthcare

16:12

                            At the close of Hong Kong stocks, the Hang Seng Index closed up 1.75%, the Hang Seng Tech Index closed up 2.59%, WuXi AppTec (02359.HK) closed up 7.23%, and JD.com (09618.HK) closed up 7.29%.
                        
16:10

                            Hong Kong stocks closed: Hang Seng Index rose 1.75% Hang Seng Technology Index rose 2.59%
                        
                            At the close of Hong Kong stocks, the Hang Seng Index rose 1.75%, and the Hang Seng Technology Index rose 2.59%. The pharmaceutical sector led the gains, with WuXi AppTec and JD.com rising more than 7%, Meituan and Vanke rising more than 5%, and Alibaba rising more than 4%.
                        
12:01

                            Hong Kong Stocks Midday Review: Hang Seng Index rose 2.33% and Hang Seng Technology Index rose 3.17%
                        
                            At the close of Hong Kong stocks at noon, the Hang Seng Index rose 2.33% and the Hang Seng Technology Index rose 3.17%. Pharmaceutical stocks led the gains, with JD.com and WuXi AppTec rising more than 7%, Alibaba and Meituan rising more than 6%, and WuXi Biologics rising more than 5%.
                        
09:44

                            Hong Kong-listed pharmaceutical stocks strengthened, with WuXi AppTec rising more than 5%
                        
                            Hong Kong-listed pharmaceutical stocks strengthened, with WuXi AppTec rising more than 5%, followed by WuXi Biologics, CStone Pharmaceuticals, Corning Life Sciences, and Tigermed.
                        
09:36

                            The Hong Kong stock biopharmaceutical sector rose in early trading, with WuXi AppTec (02359.HK) rising more than 5%, WuXi Biologics (02269.HK) rising more than 4%, BeiGene (06160.HK), Tiger Pharmaceuticals (03347.HK) and others following suit.
                        
18:47

                            Novo Nordisk: Phase 3 clinical trial of 7.2mg semaglutide reached the primary endpoint, with a 20.7% weight loss in 72 weeks
                        
                            On January 17, local time, Novo Nordisk announced the main results of the Phase 3b clinical trial STEP UP. In the STEP UP obesity trial, once-weekly subcutaneous injection of 7.2 mg semaglutide resulted in a 20.7% weight loss at 72 weeks and an 18.7% weight loss regardless of treatment compliance. The trial met its primary endpoint, with 7.2 mg of semaglutide demonstrating statistically significant and superior weight loss compared with placebo at week 72.
                        
21:29

                            LVMH surpasses Novo Nordisk to regain its position as Europe's largest listed company.
                        
21:03

                            Novo Nordisk's weight loss drugs Ozempic and Wegovy are in the spotlight in Medicare price negotiations.
                        
05:02

                            Eli Lilly (LLY.N) closed down 6.6%, its biggest one-day drop since March 2021.
                        
00:41

                            Pfizer plans to sell about 700 million Haleon shares
                        
                            Pfizer plans to sell approximately 700 million shares of Haleon.
                        
22:42

                            Eli Lilly (LLY.N) fell 5%, its biggest intraday drop since November 15.
                        
22:42

                            Eli Lilly's decline widened to 5%, the biggest intraday drop since November 15
                        
                            Eli Lilly's losses widened to 5%, its biggest intraday drop since November 15.
                        
22:35

                            Eli Lilly (LLY.N) fell 2.6 percent as it forecast weak fourth-quarter sales of its diet pills.
                        
22:03

                            Eli Lilly (LLY.N) expects revenue to be between $58 billion and $61 billion in 2025, compared with a market estimate of $58.72 billion; revenue growth in 2025 is expected to come from new drugs JAYPIRCA, EBGLYSS, OMVOH and KISUNLA.
                        
22:02

                            Eli Lilly (LLY.N) updated its 2024 revenue guidance, expecting revenue of approximately $13.5 billion in the fourth quarter of 2024 and approximately $45 billion in 2024.
                        
1737360742
104105
3

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Trends

AI Tesla electric vehicle China AI bitcoin Chinese Company South Korea Tencent Apple

Weekly Highlights

                                    U.S. President Trump raised the idea of a joint venture with TikTok, saying it was one of many suggestions.
                            2025-01-21

                                    Bitcoin stood above $104,000 per coin, up 4.09% on the day.
                            2025-01-17

                                    Morgan Stanley lowered its target price for Tencent Holdings from HK$570.00 to HK$550.00
                            2025-01-15

                                    US President Trump: Under a possible deal, the United States may impose some or greater degree of regulation on TikTok.
                            2025-01-21

                                    Hong Kong stocks opened: Hang Seng Index opened 1.02% higher, Hang Seng Technology Index opened 1.21% higher
                            2025-01-21